Feeling reasonably good today; no evident symptoms. About 10:30 AM, I went over to the golf club and hit 50-60 practice balls. Afterward, I did feel some fatigue, but not enough to prevent me from booking a tee time for tomorrow. I'll take a cart in case I feel the need to bail out.
Later, on the Internet, PLX4032 was in today's OncologySTAT with a repeat of the prior Phase I trial and a more recent article from the 2009 October 1 Elesvier Global Medical News, "Targeted Therapy PLX4032 Takes Center Stage in Metastatic Melanoma." Like Gleevec, PLX4032 requires a gene mutation, BRAF/V600. Unlike Gleevec which requires requires C-KIT mutation which occurs in about 5% of melanoma sufferers, the V600 mutation occurs in about 60% of patients.
A Phase II trial is expected to be completed by the end of 2009, with a randomized Phase III trial to begin shortly thereafter. Something to keep in mind for possible next steps.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment